Previous 10 | Next 10 |
Invitae expands capabilities of its advanced clinical chatbot Gia, enhancing telemedicine support for patients and clinicians -- Clinicians can now share test results reports with patients directly, reducing delays and need for in-person visits -- PR Newswire SAN F...
Invitae to Present at The Cowen 41st Annual Healthcare Conference PR Newswire SAN FRANCISCO , Feb. 22, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will pres...
The following slide deck was published by Invitae Corporation in conjunction with their 2020 Q4 earnings call. For further details see: Invitae Corporation 2020 Q4 - Results - Earnings Call Presentation
Invitae (NYSE: NVTA) delivered a sizzling performance in 2020, with its shares skyrocketing 159%. That sizzle fizzled somewhat last month, though, after the medical genetics company announced a dilution-causing stock offering. The company reported its fourth-quarter results afte...
Image source: The Motley Fool. Invitae (NYSE: NVTA) Q4 2020 Earnings Call Feb 17, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Invitae (NVTA) Q4 2020 Earnings Call Transcript
Invitae Corporation (NVTA) Q4 2020 Earnings Conference Call February 17, 2021 04:30 PM ET Company Participants Laura D'Angelo - Head, Investor Relations Sean George - Chief Executive Officer Shelly Guyer - Chief Financial Officer Ken Knight - Chief Operating Officer Katherine Stueland - Chief...
Invitae Corp. (NVTA) shares are down in after-hours trading after posting Q4 2020 EPS that missed analysts' expectations, though the company beat on revenue.Non-GAAP net loss increased 85% between Q4 2020 and the prior-year period from $61M to $113.1M, while net loss per share plunged nearly ...
Invitae (NVTA): Q4 Non-GAAP EPS of -$0.63; GAAP EPS of -$1.34 misses by $0.77.Revenue of $100.43M (+51.5% Y/Y) beats by $1.36M.Billable volume was ~238,000.2021 Outlook: Invitae reiterates its stated outlook for revenue growth targets of 50% - 60% annual growth over the next few years an...
Invitae Reports $279.6 Million in Annual Revenue Driven by 659,000 in Billable Volume in 2020 - Increased annual revenue by 29% and annual billable volume by 41% year-over-year - - Hosting conference call and webcast today at 4:30pm Eastern/1:30pm Pacific - PR Newswire ...
Is Pacific Biosciences The Best Biotech Stock To Buy In The Stock Market Today? In the biotech world of genome sequencing, Illumina ( NASDAQ: ILMN ) may be the undisputed market leader. But when it comes to shareholder returns in the past year, Pacific Biosciences of California ...
News, Short Squeeze, Breakout and More Instantly...
Labcorp Announces Winning Bid for Select Assets of Invitae PR Newswire Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 ...
Invitae Enters into Agreement with Labcorp for Sale of Business PR Newswire – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantial...
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance PR Newswire – Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO , April 11, 2024 /PRNewsw...